Neobe Therapeutics
PrivateLast Round
Seed
Nov 10, 2026
Total Funding Raised
$9.76M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Neobe Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Seed round in November 2026.
Neobe Therapeutics is a biotechnology company developing a synthetic biology platform to engineer programmable bacteria that remodel the microenvironment of solid tumors to improve immunotherapy efficacy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neobe Therapeutics Comparables
Compare Neobe Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| mbiomics GmbH | 86% | |
| Baccine Ltd. | 84% | |
| Ernest Pharmaceuticals | 83% |
For institutional investors. Book with your work email.
Neobe Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 10, 2026 | ||||
| Seed | Feb 29, 2024 | ||||
| Pre Seed | Nov 22, 2022 |
For institutional investors. Book with your work email.
Neobe Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deep Science Ventures | Seed |
| Pioneer Group | Seed |
| Innovate UK | Seed, Pre Seed |
| 2048 Ventures | Seed |
| Empirical Ventures | Seed |
| Faber Ventures | Seed |
| Proven Connect | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2026
$7M round led by Arc Ventures.
- Apr 24, 2026
Monthly visitors increased 51% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withNov 10, 2026
In 2026, Neobe Therapeutics Ltd partners with UCY and Barts Cancer Institute in London to test an engineered bacterial platform in a model of treatment-resistant triple-negative breast cancer.
- hiresNov 10, 2026
Neobe Therapeutics Ltd appoints internationally recognized immuno-oncology expert Laura Chow as Chief Medical Officer on Nov 10th '26 to lead clinical development and prepare the technology’s first human trial.
- expands_offices_toNov 10, 2026
Neobe Therapeutics Ltd plans to establish a presence in Lisbon to build partnerships with Portugal’s biotechnology and health sciences ecosystem on Nov 10th '26.
- is_developingNov 10, 2026
In Nov '26, Neobe Therapeutics Ltd, based in United Kingdom, is developing genetically modified bacteria to help treatments and immune-system cells enter solid tumors, with its NEO22 program in preclinical development ahead of an IND submission scheduled for 2028.
- receives_financingNov 10, 2026
Neobe Therapeutics Ltd receives $6.8M in Seed financing in the initial phase of its seed round on Nov 10th '26, led by ARC Ventures with participation from Faber, Macmillan Ventures, Proven Connect, Empirical Ventures and 2048 Ventures, to accelerate NEO22 development and prepare for clinical trials.
For institutional investors. Book with your work email.
Neobe Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neobe Therapeutics's valuation, stock price, and market status.
Is Neobe Therapeutics a public or private company?
Neobe Therapeutics is a private company.
What is the current stock price of Neobe Therapeutics?
Neobe Therapeutics is a private company, so its shares have no public market price. Caplight tracks Neobe Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neobe Therapeutics worth (valuation)?
Valuation information for Neobe Therapeutics is not publicly available.
Can I buy Neobe Therapeutics stock?
Neobe Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neobe Therapeutics's last funding round?
Neobe Therapeutics's most recent funding round was Seed on November 10, 2026.
Who are the main investors in Neobe Therapeutics?
Key investors in Neobe Therapeutics include Pioneer Group, Arc Ventures, Discovery Park Ventures.
Will Neobe Therapeutics IPO soon?
No public IPO plans have been announced for Neobe Therapeutics.
How can I track Neobe Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Neobe Therapeutics's shares on secondary markets.